METHOTREXATE | N214121 | ACCORD HEALTHCARE INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | St. Jude Children's Research Hospital | 206 | 2017-06-15 → 2027-06 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 488 | 2014-05-19 → 2027-02-25 | |
| Phase 2 | Active | St. Jude Children's Research Hospital | 125 | 2014-05-14 → 2027-09 | |
| Phase 2 | Active | Memorial Sloan Kettering Cancer Center | 17 | 2020-03-30 → 2027-03 | |
| Phase 2 | Active | M.D. Anderson Cancer Center | 88 | 2011-10-05 → 2027-10-31 | |
| Phase 3 | Active | UNICANCER | 318 | 2007-03 → 2026-12 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 97 | 2009-09-01 → 2027-01-06 | |
| Phase 2 | Active | University Hospital, Bordeaux | 128 | 2020-12-03 → 2026-06 | |
| Phase 1/2 | Active | St. Jude Children's Research Hospital | 50 | 2016-01-29 → 2031-10 | |
| Phase 2 | Active | City of Hope Medical Center | 260 | 2001-10-16 → 2027-03-29 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Total Spending
$57.2M
Total Claims
2,414,242
Beneficiaries
551,528
Avg Cost/Unit
$0.63
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
9 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 16, 2026 | SUPPL -5 | View Letter (PDF) |
| Jun 2, 2025 | SUPPL -3 | View Letter (PDF) |
| Jun 2, 2025 | SUPPL -4 | View Letter (PDF) |
| Mar 11, 2022 | SUPPL -1 | View Letter (PDF) |
| Aug 25, 2020 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.